Total population, n=5,094
- treated in buffer zones, n=1,637
- eligible for randomization, n=3,457

Enrollment

Clusters (n=8)

Intervention (n=1,110)
- Clusters (n=8)

Allocation

Control (n=2,347)
- Clusters (n=8)

Eligible, n=1,026
- Not eligible, n= 84
  - Pregnant (n= 27, 25 received alternative drug)
  - Below 1 year of age (n=26, received no drugs)
  - Allergic to sulphadoxine-pyrimethamine (n=3)
  - Received full dose of antimalarials <14d (n=23)
  - Unable to consent (mental illness, n=2; alcoholic, n=4)

Refused completely, n= 33
- Religious reasons (n= 5)
- No reason given (n=27)

Treated with gametocytocidal drug combination:
- Received dose 1 under supervision, n=993
- Received dose 1-2 under supervision, n=990
- Received dose 1-3 under supervision, n=978 (35 no PQ)

Arrived after the initial intervention (n=91):
- Received dose 1 under supervision, n=91
- Received dose 1-2 under supervision, n=91
- Received dose 1-3 under supervision, n=91 (3 no PQ)

Refused completely, n= 84
- Religious reasons (n= 3)
- No reason given (n=81)

Treated with placebo:
- Received dose 1 under supervision, n=2,184
- Received dose 2-3, n=2,184 (no supervision)

Arrived after the initial intervention (n=114):
- Received dose 1 under supervision, n=114
- Received dose 2-3 under supervision, n=114

Analysis

Passive case detection: 1,201 individuals, 7 months
Active case detection: n=149, 1043 person-months
Cross-sectional surveys, n=1303 observations
  Jan-Feb n=284; Apr n=261; May n= 227; Jun n= 172; Jul n=360

Passive case detection: n=2,461, 7 months
Active case detection: n=143, 1001 person-months
Cross-sectional surveys, n=1130 observations
  Jan-Feb n=212; April n 223; May n=223; June n=172; Jul n=300